Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study
- PMID: 30852071
- DOI: 10.1016/j.nmd.2019.02.002
Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study
Abstract
The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
Keywords: Composite endpoint; Duchenne muscular dystrophy; Upper limb function and strength; forced vital capacity; peak expiratory flow; pulmonary function.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials.PLoS One. 2016 Sep 20;11(9):e0162542. doi: 10.1371/journal.pone.0162542. eCollection 2016. PLoS One. 2016. PMID: 27649492 Free PMC article.
-
Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.PLoS One. 2015 Feb 2;10(2):e0113999. doi: 10.1371/journal.pone.0113999. eCollection 2015. PLoS One. 2015. PMID: 25643053 Free PMC article. Clinical Trial.
-
Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients.Neuromuscul Disord. 2013 Feb;23(2):139-48. doi: 10.1016/j.nmd.2012.10.022. Epub 2012 Dec 5. Neuromuscul Disord. 2013. PMID: 23219352
-
Clinical pulmonary function testing in Duchenne muscular dystrophy.Paediatr Respir Rev. 2019 Apr;30:9-12. doi: 10.1016/j.prrv.2018.08.004. Epub 2018 Oct 4. Paediatr Respir Rev. 2019. PMID: 30413352 Review.
-
Muscle-MRI and Functional Levels for the Evaluation of Upper Limbs in Duchenne Muscular Dystrophy: A Critical Review of the Literature.Medicina (Kaunas). 2022 Mar 17;58(3):440. doi: 10.3390/medicina58030440. Medicina (Kaunas). 2022. PMID: 35334617 Free PMC article. Review.
Cited by
-
Evaluation, Acceptance, and Qualification of Digital Measures: From Proof of Concept to Endpoint.Digit Biomark. 2021 Mar 23;5(1):53-64. doi: 10.1159/000514730. eCollection 2021 Jan-Apr. Digit Biomark. 2021. PMID: 33977218 Free PMC article. Review.
-
Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.Nat Med. 2023 Jan;29(1):95-103. doi: 10.1038/s41591-022-02045-1. Epub 2023 Jan 19. Nat Med. 2023. PMID: 36658421 Free PMC article.
-
Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study.Neurology. 2021 Jan 26;96(4):e587-e599. doi: 10.1212/WNL.0000000000011051. Epub 2020 Oct 16. Neurology. 2021. PMID: 33067401 Free PMC article.
-
Extracellular Matrix Proteomics: The mdx-4cv Mouse Diaphragm as a Surrogate for Studying Myofibrosis in Dystrophinopathy.Biomolecules. 2023 Jul 12;13(7):1108. doi: 10.3390/biom13071108. Biomolecules. 2023. PMID: 37509144 Free PMC article. Review.
-
Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy.Pflugers Arch. 2021 Dec;473(12):1813-1839. doi: 10.1007/s00424-021-02623-1. Epub 2021 Sep 22. Pflugers Arch. 2021. PMID: 34553265 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources